A real-world study from Siriraj Hospital in Thailand reported that total neoadjuvant therapy improves tumor response rates in locally advanced rectal cancer outside controlled trial settings. The analysis compared preoperative treatment strategies across three distinct neoadjuvant approaches, using real-world outcomes captured through clinical practice. Published in BMC Cancer, the report adds to growing evidence that sequencing systemic therapy and chemoradiotherapy before surgery can improve measurable response in populations treated in routine care. While clinical endpoints vary across studies, the authors emphasized the consistency of response improvements when neoadjuvant intensity is used broadly. For clinicians and trial designers, the report is a reminder that real-world data can support de-escalation or optimization discussions by indicating whether treatment frameworks that work in trials translate to everyday oncology workflows.